Laurence de Schoulepnikoff
Operationeel Directeur bij OSE IMMUNOTHERAPEUTICS
Actieve functies van Laurence de Schoulepnikoff
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Operationeel Directeur | 16-01-2022 | - |
| Corporate Officer/Principal | 20-12-2021 | 16-01-2022 | |
| Swiss Healthcare Licensing Group | Directeur/Bestuurslid | - | - |
Tridek-One Therapeutics SAS
 Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Algemeen Directeur | - | - |
Loopbaan van Laurence de Schoulepnikoff
Eerdere bekende functies van Laurence de Schoulepnikoff
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Operationeel Directeur | 01-01-2019 | - |
Opleiding van Laurence de Schoulepnikoff
| École Polytechnique Fédérale de Lausanne | Graduate Degree |
Statistieken
Internationaal
| Zwitserland | 4 |
| Frankrijk | 3 |
Operationeel
| Chief Operating Officer | 2 |
| Corporate Officer/Principal | 1 |
| Graduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| OSE IMMUNOTHERAPEUTICS | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Health Technology |
| Swiss Healthcare Licensing Group | |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Commercial Services |
